

FINANCIAL RESULTS

BUSINESS SEGMENT SALES

EPS

ABOVE PREVIOUS GUIDANCE

\$0.52 ADJUSTED DILUTED EPS

\$0.52 REPORTED DILUTED EPS

SALES WORLDWIDE

+10.8%
ON OPERATIONAL BASIS*

\$5.2BN
SALES WORLDWIDE



DIAGNOSTICS

1.2BN
+8.7%



NUTRITION

1.7BN
+3.9%

ON OPERATIONAL BASIS*
SALES COMPARED TO 2Q 2014



MEDICAL DEVICES

1.3BN
+3.1%



BRANDED GENERICS PHARMACEUTICALS

977MN
+46.0%

BUSINESS HIGHLIGHTS

SALES GROWTH



Branded Generics Pharmaceuticals

The Branded Generics Pharmaceuticals business delivered strong double-digit sales growth including above market growth in India, China and Colombia.

KEY NEW ACCOUNTS



Diagnostics

Diagnostics' customer-focused solutions continue to win key new accounts, driving above-market sales growth.

INNOVATION



FreeStyle® Libre

Adoption of Abbott's revolutionary new FreeStyle® Libre Flash Glucose Monitoring System continues to drive international sales growth for the Diabetes business.

EMERGING MARKETS



+20.6%

Emerging market sales up 20.6% driven by recent acquisitions and strong growth across most businesses.

ON OPERATIONAL BASIS*

*Operational results are non-GAAP as they exclude the impact of foreign exchange. Total sales and Branded Generics Pharmaceuticals sales growth also include the impact of recent acquisitions. EPS and sales results are shown on continuing basis.

For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 22, 2015, available at www.abbottinvestor.com.

FORWARD LOOKING STATEMENTS

Some statements contained here may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2014, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.